News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boehringer Ingelheim Corporation Remains Bullish on R&D and India



11/14/2012 7:24:32 AM

Boehringer Ingelheim's research driven business model is worth emulating by the Indian pharma companies. The 13.2 billion euro German drug company has one of the highest R&D spends (24% of the revenues) among the large pharma companies of the world. Globally spends on R&D are being cut down by the innovator companies amidst challenging environment involving issues around patients, clinical trials and the general tilt towards generics. Despite this, the family-owned innovative pharma company remains bullish on R&D. The company has a strong pipeline of 10 research products in phase III trials. "One of the benefits of being privately-held is that the promoter family thinks in generations and not in quarterly reports. This gives our R&D colleagues the opportunity to take some more time for careful planning. This, along with a bit of luck, gives us the privilege of a well-filled pipeline," says Dr Andreas Barner, chairman of the company, in an interview with ET.

Read at India Times


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES